Breindahl, Niklas
Tolsgaard, Martin G.
Henriksen, Tine B.
Roehr, Charles C.
Szczapa, Tomasz
Gagliardi, Luigi
Vento, Maximo
Støen, Ragnhild
Bohlin, Kajsa
van Kaam, Anton H.
Klotz, Daniel
Durrmeyer, Xavier
Han, Tongyan
Katheria, Anup C.
Dargaville, Peter A.
Aunsholt, Lise
Article History
Received: 13 December 2022
Revised: 20 March 2023
Accepted: 1 April 2023
First Online: 4 May 2023
Competing interests
: P.A.D. has received in kind support from Chiesi Farmaceutici for conducting the OPTIMIST-A trial and has undertaken consultancies for surfactant manufacturers Chiesi and Abbvie.
: This study did not require patient consent. We collected electronic informed consent from all LISA experts prior to study participation.